enGene Therapeutics Inc. (ENGN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

enGene Therapeutics Inc. (ENGN) closed at USD 1.56 on 2026-10-14, a change of -80.3 % over the past year, with a market capitalization of USD 114.6M.

enGene Therapeutics Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

enGene Therapeutics Inc. key figures

Previous close

USD 1.56 (2026-10-14)

1-year change

-80.3 %

Market cap

USD 114.6M

Enterprise value

USD -118.45M

P/E ratio (trailing)

-0.83

P/E ratio (forward)

-1.18

EPS (trailing)

-2.07

EPS (forward)

-1.45

PEG ratio

n/a

Price to book

0.50

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.93

Employees

81

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About enGene Therapeutics Inc.

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for enGene Therapeutics Inc. and compare it with other stocks.